SCHEMBL939680

SCHEMBL939680

COc1cc(C)c(S(=O)(=O)N(C)Cc2nc3c(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)cccc3n2C)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 11/20 0.46
CYP3A4 P08684 10/20 0.46
CYP1A2 P05177 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.41
CYP2C9 P11712 10/20 0.40
TSHR P16473 7/20 0.40
ALDH1A1 P00352 5/20 0.40
HIF1A Q16665 5/20 0.40
CYP2C19 P33261 4/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 3/20 0.38
USP2 O75604 2/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
KMT2A Q03164 1/20 0.38
GFER P55789 1/20 0.37
BDKRB1 P46663 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938403 0.84 CYP3A4 (0.46) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL940776 0.83 CYP2D6 (0.47) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL939647 0.82 CYP2D6 (0.45) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL940068 0.80 PARP1 (0.42) SMN1; SMN2TSHRUSP2BDKRB1
SCHEMBL937726 0.80 CYP3A4 (0.44) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL938881 0.80 CYP3A4 (0.47) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL939284 0.80 CYP2D6 (0.47) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9
SCHEMBL937873 0.79 PARP1 (0.41) SMN1; SMN2TSHRALDH1A1HPGDUSP2
SCHEMBL939152 0.79 CYP3A4 (0.45) CYP2D6CYP3A4CYP1A2CYP2C9TSHR
SCHEMBL938443 0.79 CYP3A4 (0.42) CYP2D6CYP3A4CYP1A2SMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP claimed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US claimed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US claimed
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles BDKRB1, BDKRB2, BRD1 CYP2D6 1223/4885CYP3A4 253/4885CYP1A2 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.